HIV and AIDS: Vaccine

Lord Avebury Excerpts
Monday 1st December 2014

(9 years, 11 months ago)

Lords Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Baroness Northover Portrait Baroness Northover
- Hansard - - - Excerpts

I will be speaking at the launch of that report later this afternoon, and no doubt we will have further discussions about it. One of the striking things about this is that in terms of research and development funding for new product development in 2012—the most recent figures available—33.6% went to HIV/AIDS, 17.1% towards malaria and 15% towards TB, so it is not a neglected area. But research into the vaccine is proving exceptionally difficult and the trials have proved disappointing. It is therefore necessary to move back to basic research and drive it forward that way. Meanwhile, a lot of effort is going into research and development on treatments. As the noble Lord will know, over the past decade there have been great advances in treatment. One of the key things, as my noble friend Lord Howe just indicated, is making sure that people know their status and are treated.

Lord Avebury Portrait Lord Avebury (LD)
- Hansard - -

My Lords, I declare an interest as co-chair of the All-Party Group for Child Health and Vaccine Preventable Diseases. We understand that an effective vaccine against HIV/AIDS is still a long way off, but could my noble friend give us a progress report on two relevant product development partnerships that are funded by DfID? They are the International AIDS Vaccine Initiative, and the TB Alliance’s development of new drugs for TB patients who are also infected by HIV.

Baroness Northover Portrait Baroness Northover
- Hansard - - - Excerpts

My noble friend rightly highlights the link between HIV and TB. The IAVI has developed new approaches to HIV vaccine research by focusing on the needs of developing countries and early-stage research. The TB Alliance has four combinations of drugs in late-stage development, and will soon launch a trial of a combination of drugs that are suitable for those who are co-infected with both diseases.